Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Amortization of Deferred Charges: 2018-2023

Historic Amortization of Deferred Charges for Avadel Pharmaceuticals (AVDL) over the last 6 years, with Dec 2023 value amounting to $2.8 million.

  • Avadel Pharmaceuticals' Amortization of Deferred Charges rose 512.54% to $1.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $6.1 million, marking a year-over-year increase of 384.94%. This contributed to the annual value of $2.8 million for FY2023, which is 53.80% down from last year.
  • According to the latest figures from FY2023, Avadel Pharmaceuticals' Amortization of Deferred Charges is $2.8 million, which was down 53.80% from $6.1 million recorded in FY2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Amortization of Deferred Charges peaked at $6.5 million during FY2020, and registered a low of $1.2 million during FY2021.
  • For the 3-year period, Avadel Pharmaceuticals' Amortization of Deferred Charges averaged around $3.4 million, with its median value being $2.8 million (2023).
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first tumbled by 80.87% in 2021, then skyrocketed by 384.94% in 2022.
  • Over the past 5 years, Avadel Pharmaceuticals' Amortization of Deferred Charges (Yearly) stood at $6.0 million in 2019, then increased by 8.82% to $6.5 million in 2020, then crashed by 80.87% to $1.2 million in 2021, then surged by 384.94% to $6.1 million in 2022, then tumbled by 53.80% to $2.8 million in 2023.